merscov
treatment
prophylaxi
neutral
monoclon
antibodi
common
marmoset
b
r
c
effect
antivir
treatment
merscov
urgent
need
merscovneutr
monoclon
antibodi
isol
convalesc
mer
patient
previous
shown
treatment
result
reduc
diseas
viru
titer
mous
model
merscov
infect
test
prophylact
efficaci
common
marmoset
model
merscov
infect
intraven
administr
one
day
viru
challeng
result
high
level
merscovneutr
activ
circul
blood
clinic
moder
benefit
treatment
includ
reduc
respiratori
involv
although
viral
lung
load
reduc
anim
compar
control
fewer
patholog
chang
lung
thu
prophylact
treatment
could
implement
reduc
diseas
burden
contact
confirm
merscov
patient
middl
east
respiratori
syndrom
coronaviru
merscov
caus
sever
respiratori
diseas
high
casefat
rate
human
current
approv
treatment
mer
human
monoclon
antibodi
isol
memori
b
cell
deriv
convalesc
mer
patient
uk
bermingham
et
al
corti
et
al
neutral
merscov
bind
receptor
bind
domain
merscov
spike
protein
corti
et
al
balbc
mice
transient
express
human
lung
tissu
transduct
adenoviru
vector
express
human
treat
one
day
challeng
merscov
show
signific
reduct
viru
titer
lung
compar
control
corti
et
al
ifnarko
mice
treatment
one
day
inocul
merscov
result
reduc
diseas
indic
bodyweight
loss
well
signific
reduct
lung
viru
titer
corti
et
al
promis
result
prompt
us
test
prophylact
efficaci
treatment
distinct
anim
model
mer
common
marmoset
support
licensur
human
use
contrast
mice
common
marmoset
natur
suscept
merscov
develop
moder
sever
diseas
upon
infect
falzarano
et
al
anim
experi
approv
institut
anim
care
use
committe
rocki
mountain
laboratori
niaid
nih
carri
certifi
staff
associ
assess
accredit
laboratori
anim
care
aaalac
intern
accredit
facil
accord
institut
guidelin
anim
use
follow
guidelin
basic
principl
unit
state
public
health
servic
polici
human
care
use
laboratori
anim
guid
care
use
laboratori
anim
infecti
work
merscov
approv
institut
biosafeti
committe
perform
high
contain
facil
rml
sampl
inactiv
perform
accord
standard
oper
procedur
remov
specimen
high
contain
approv
institut
biosafeti
committe
twelv
common
marmoset
callithrix
jacchu
year
old
randomli
assign
two
group
six
anim
anim
first
group
male
femal
intraven
infus
mgkg
mab
second
group
male
femal
intraven
infus
human
monoclon
antibodi
neutral
human
respiratori
syncyti
viru
hrsv
use
http
receiv
januari
accept
januari
control
corti
et
al
monoclon
antibodi
infus
femor
vein
volum
ml
depend
bodyweight
merscovneutr
activ
serum
determin
sever
timepoint
infus
use
microneutr
assay
tcid
describ
previous
de
wit
et
al
serum
sampl
collect
day
administr
contain
high
level
merscov
neutral
activ
merscov
neutral
antibodi
detect
control
mabtreat
anim
fig
although
neutral
titer
serum
anim
drop
first
last
measur
reciproc
serum
neutral
titer
remain
high
throughout
experi
anim
rang
fig
twentyfour
hour
administr
neutral
antibodi
prepar
anim
inocul
merscov
strain
combin
four
rout
total
dose
dose
tcid
intranas
nare
oral
intratrach
eye
dmem
contain
tcid
ml
establish
previous
falzarano
et
al
determin
prophylact
efficaci
mab
treatment
inocul
merscov
anim
score
twice
daili
presenc
diseas
sign
use
standard
score
sheet
previous
develop
publish
common
marmoset
falzarano
et
al
fig
serolog
clinic
virolog
find
common
marmoset
inocul
merscov
strain
treat
prophylact
two
group
six
marmoset
intraven
infus
mgkg
control
mab
black
circl
merscov
neutral
mab
red
squar
inocul
merscov
h
later
dpi
serum
collect
test
presenc
merscov
neutral
antibodi
inocul
anim
observ
twice
daili
clinic
sign
diseas
score
use
clinic
score
system
prepar
common
marmoset
person
blind
treatment
assign
b
dpi
clinic
exam
perform
bodyweight
c
respir
rate
determin
radiograph
taken
radiograph
use
score
individu
lung
lobe
sever
pulmonari
infiltr
clinic
veterinarian
blind
treatment
assign
accord
standard
score
system
normal
mild
interstiti
pulmonari
infiltr
moder
pulmonari
infiltr
perhap
partial
cardiac
border
effac
small
area
pulmonari
consolid
seriou
interstiti
infiltr
alveolar
pattern
air
bronchogram
cumul
xray
score
sum
score
four
individu
lung
lobe
per
anim
e
dpi
anim
euthan
tissu
sampl
collect
lung
lobe
rna
extract
qrtpcr
target
upe
perform
viral
load
determin
tcid
equival
per
gram
tissu
describ
previous
de
wit
et
al
geometr
mean
viral
load
standard
deviat
shown
tissu
f
asterisk
indic
statist
signific
determin
use
unpair
ttest
multipl
comparison
use
holmsidak
method
p
p
p
score
done
individu
throughout
studi
person
blind
assign
anim
control
mabor
group
regardless
treatment
anim
show
sign
diseas
inocul
merscov
howev
diseas
score
appear
lower
anim
treat
although
differ
statist
signific
day
post
infect
dpi
fig
clinic
exam
perform
anesthet
anim
dpi
bodyweight
respir
rate
determin
chest
radiograph
taken
anim
lost
bodyweight
inocul
merscov
dpi
bodyweight
loss
observ
anim
statist
significantli
less
control
anim
fig
anim
treat
control
mab
show
increas
respir
rate
wherea
anim
treat
show
increas
respir
rate
respir
rate
significantli
higher
control
mabtreat
anim
anim
dpi
dpi
fig
chest
radiograph
obtain
dpi
anim
analyz
presenc
pulmonari
infiltr
clinic
veterinarian
blind
group
assign
anim
show
anim
significantli
lower
cumul
score
control
mabtreat
anim
fig
indic
anim
fewer
pulmonari
infiltr
suggest
respiratori
diseas
less
sever
anim
one
common
marmoset
control
group
reach
preestablish
human
endpoint
criteria
dpi
final
day
experi
sever
respiratori
sign
clinic
score
sever
hypothermia
bodi
temperatur
baselin
data
shown
dpi
anim
euthan
determin
viral
load
assess
patholog
chang
variou
tissu
tissu
respiratori
tract
includ
sampl
four
lung
lobe
collect
analysi
rna
extract
mg
tissu
use
onestep
realtim
rtpcr
qrtpcr
detect
upe
corman
et
al
describ
previous
de
wit
et
al
statist
differ
viral
load
versu
control
mabtreat
anim
fig
viral
load
determin
qrtpcr
viru
titrat
presenc
neutral
antibodi
would
hard
interpret
sinc
neutral
antibodi
would
still
present
tissu
titrat
assay
perform
previous
unbound
antibodi
could
potenti
neutral
viru
titrat
make
neg
find
difficult
interpret
upon
necropsi
area
lung
lobe
affect
gross
lesion
estim
boardcertifi
veterinari
pathologist
blind
group
assign
anim
although
gross
lung
lesion
observ
control
mabtreat
anim
statist
significantli
smaller
area
lung
affect
lesion
anim
controlmabtr
anim
fig
lung
weight
determin
necropsi
calcul
lung
weight
bodyweight
ratio
indic
pneumonia
ratio
significantli
lower
anim
control
fig
histolog
assess
lung
tissu
boardcertifi
veterinari
pathologist
blind
group
assign
anim
show
anim
except
one
anim
group
develop
typic
multifoc
coalesc
moder
mark
subacut
bronchointerstiti
pneumonia
type
ii
pneumocyt
hyperplasia
fig
previous
observ
marmoset
inocul
merscov
falzarano
et
al
merscov
antigen
could
detect
immunohistochemistri
area
affect
lesion
use
inhous
rabbit
polyclon
antibodi
merscov
describ
elsewher
fig
quantif
percentag
merscov
antigenposit
cell
lung
histolog
slide
perform
use
aperio
digit
slide
scanner
imagescop
posit
pixel
count
algorithm
describ
previous
basel
et
al
show
statist
significantli
fewer
antigenposit
cell
present
lung
anim
lung
control
anim
fig
one
anim
without
histolog
lesion
viral
rna
detect
lung
lobe
qrtpcr
detect
conjunctiva
pharynx
nasal
mucosa
whether
lack
lesion
viru
replic
lung
anim
result
treatment
sampl
error
problem
viru
inocul
could
determin
taken
togeth
prophylact
treatment
result
moder
clinic
benefit
includ
reduc
respiratori
involv
fewer
patholog
chang
lung
marmoset
result
line
studi
common
marmoset
treatment
monoclon
antibodi
result
less
sever
respiratori
diseas
de
wit
et
al
studi
rhesu
macaqu
prophylact
treatment
merscov
neutral
mab
result
reduc
patholog
lung
volum
use
comput
tomographi
johnson
et
al
note
shown
bind
epitop
overlap
potent
term
viral
neutral
corti
et
al
thu
studi
support
implement
prophylact
treatment
reduc
health
care
centerbas
outbreak
transmiss
close
contact
confirm
merscov
patient
therapeut
efficaci
assess
marmoset
model
due
moder
clinic
benefit
observ
upon
prophylact
treatment
shown
mous
model
merscov
infect
corti
et
al
howev
therapeut
efficaci
sever
merscov
neutral
antibodi
shown
mous
model
agraw
et
al
corti
et
al
li
et
al
pascal
et
al
qiu
et
al
zhao
et
al
far
clinic
benefit
nonhuman
primat
studi
modest
chen
et
al
de
wit
et
al
van
doremalen
et
al
thu
would
like
efficaci
therapeut
treatment
combin
merscovneutr
antibodi
antivir
treatment
ribavirin
ifn
lopinavir
shown
therapeut
efficaci
nonhuman
primat
chan
et
al
falzarano
et
al
limit
studi
reflect
debat
valu
anim
diseas
model
mer
review
basel
et
al
neither
mous
nonhuman
primat
model
repres
hallmark
human
mer
rodent
lack
natur
suscept
merscov
overcom
express
human
receptor
differ
mean
nonhuman
primat
model
util
high
infecti
dose
partial
artifici
inocul
rout
lead
immedi
acut
transient
diseas
fatal
common
marmoset
current
insuffici
data
address
valu
one
model
review
basel
et
al
therefor
treatment
efficaci
data
rodent
nonhuman
primat
model
need
consid
interpret
care
may
necessarili
reflect
outcom
human
evalu
model
seem
need
select
treatment
modal
prior
human
clinic
trial
thu
import
tool
mer
countermeasur
develop
edw
ff
evh
ao
elh
gs
ds
rg
mz
hf
conflict
declar
ec
dc
employe
vir
biotechnolog
hold
share
vir
biotechnolog
patholog
find
lung
common
marmoset
inocul
merscov
treat
prophylact
two
group
six
common
marmoset
intraven
infus
mgkg
control
mab
black
merscov
neutral
mab
red
inocul
merscov
h
later
dpi
anim
euthan
area
lung
lobe
affect
gross
lesion
score
boardcertifi
veterinari
pathologist
blind
treatment
receiv
anim
lung
weigh
determin
lung
weight
bodyweight
ratio
b
sampl
collect
histolog
analysi
tissu
stain
hematoxylin
eosin
rabbit
polyclon
antibodi
ihc
one
repres
imag
chosen
group
control
mabtreat
anim
c
slide
four
lung
lobe
anim
stain
polyclon
antibodi
digit
antigenposit
pixel
quantifi
use
imagescop
posit
pixel
algorithm
percentag
antigenposit
pixel
calcul
number
pixel
stain
merscov
antigen
divid
total
number
stain
pixel
ie
nonstain
area
air
space
exclud
analysi
asterisk
indic
statist
signific
determin
use
unpair
ttest
multipl
comparison
use
holmsidak
method
p
p
